The global obesity epidemic has catalyzed one of the most intense periods of pharmaceutical innovation in history. This week, as specialists in metabolic disease and endocrinology convened in Milan for the annual meeting of the European Association for the Study of Diabetes (EASD), the atmosphere was charged with high-stakes competition. For the world’s leading drugmakers, the conference served as a critical arena to unveil clinical data, refine long-term strategies, and court the prescribers who will dictate the market’s trajectory over the next decade.
While the current market landscape is dominated by the colossal success of Eli Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide)—products generating billions in monthly revenue—the industry narrative is rapidly shifting. The focus has moved beyond mere efficacy toward a "next generation" of treatments: medicines that promise deeper weight loss, improved tolerability profiles, and greater convenience for the patient.
Main Facts: The Evolving Obesity Pipeline
The obesity market is no longer a duopoly, though its original architects remain the primary drivers of clinical innovation. The data presented at EASD 2026 underscored three primary themes: the rise of "combination therapies" to maximize weight loss, the strategic transition from injectable to oral formats to improve patient adherence, and the entry of "fast followers" looking to capture market share through differentiated mechanisms of action.
At the heart of the discourse was the realization that weight loss is not a one-size-fits-all endeavor. Clinicians are increasingly seeking tools that allow for personalized titration, where a patient might start on a more tolerable "softer" agent and escalate to more potent, multi-receptor agonists as needed.
Chronology of Development: From First-Gen to Next-Gen
The evolution of obesity medicine has been remarkably swift. Just five years ago, the field was defined by relatively ineffective stimulants and limited options.
- 2021-2023: The "GLP-1 Era" began, with the clinical success of once-weekly injectables like Wegovy and Zepbound, which mimicked the gut hormone glucagon-like peptide-1.
- 2024: Industry attention pivoted toward multi-agonists, specifically targeting GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors to drive deeper metabolic changes.
- 2025: Strategic acquisitions and in-licensing deals surged, with giants like AbbVie and Boehringer Ingelheim signaling their intent to challenge the status quo.
- 2026 (Present): The EASD meeting marks the "Optimization Phase." The focus is on refining existing molecules through combination strategies (e.g., amylin-based therapies) and proving that oral versions of these blockbuster drugs can maintain the efficacy profiles of their injectable predecessors.
Supporting Data: The Science of Weight Loss
Eli Lilly’s Amylin-Zepbound Combination
Eli Lilly continues to aggressively expand its portfolio. Following the investor excitement surrounding its triple-acting drug, retatrutide, the company presented Phase 2 data at EASD regarding a novel strategy: combining Zepbound with eloralintide, an experimental drug that stimulates the digestive hormone amylin.
The results were striking. In a 48-week trial, patients with obesity receiving the highest dose of the combination therapy achieved a 23% reduction in body weight—equivalent to approximately 54 pounds. For comparison, patients on high-dose Zepbound alone saw a 15% reduction, while those on eloralintide alone achieved 12%.
Financial analysts are already factoring this into their long-term models. David Risinger of Leerink Research has forecasted that eloralintide could reach $23 billion in annual sales by 2035. Industry experts like William Blair’s Andy Hsieh suggest that amylin-based drugs, including Novo’s cagrilintide and Zealand Pharma’s petrelintide, may offer a "softer" profile with fewer gastrointestinal side effects, potentially positioning them as a foundational treatment for long-term weight maintenance.
Novo Nordisk’s Oral Transition Strategy
Novo Nordisk is leveraging its first-mover advantage to test the viability of oral administration. At EASD, the company presented "real-world" data in partnership with direct-to-consumer digital health platform Ro. The study examined patients transitioning from injectable Wegovy or Zepbound to the Wegovy pill.
The results suggested that the transition does not sacrifice efficacy; in fact, patients who continued on the oral formulation for at least three months saw an average additional weight loss of 4.1%. Perhaps most significantly, the proportion of participants classified as obese plummeted from 87% to 66% during the study period. Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, characterized these as "exciting early insights" that could redefine how clinicians individualize obesity care.
Boehringer Ingelheim and AbbVie: The Challengers
The competition is not standing idle. Boehringer Ingelheim, which previously collaborated with Lilly on the diabetes blockbuster Jardiance, is pushing forward with survodutide—a GLP-1/glucagon agonist developed in partnership with Zealand Pharma.
In a Phase 3 trial focused on the "challenging population" of patients living with both obesity and type 2 diabetes, survodutide proved highly effective. Treated patients lost an average of 13% of their body weight, compared to just 3% for the placebo group. This data is critical, as the comorbid population is often the most difficult to treat and the most likely to require medical intervention.
Meanwhile, AbbVie is betting on frequency of administration as a key differentiator. By licensing ABBV-295 from Gubra for $350 million, AbbVie is targeting a monthly injection schedule. Phase 1 trial data presented at EASD showed that even at monthly intervals, the drug stimulated an 8% weight loss, compared to less than 1% for placebo. While nausea remains a side effect—affecting one-third of participants—the potential for monthly rather than weekly shots could dramatically improve patient adherence.
Official Responses and Expert Consensus
The consensus among the medical community in Milan was one of cautious optimism. While the weight loss percentages are unprecedented, the focus is shifting toward "durability."
"We have proven that we can help patients lose significant weight," noted one lead investigator during a panel discussion. "The next challenge is proving that these patients can maintain that loss over five, ten, or twenty years without debilitating side effects or rebound weight gain."
Eli Lilly’s leadership emphasized that their combination approach is designed to provide "precision weight loss." By modulating different hormonal pathways—amylin for satiety and GIP/GLP-1 for metabolic regulation—they aim to mimic the body’s natural appetite-control systems more effectively than any single-hormone agent could.
Implications for the Future of Medicine
The implications of these developments extend far beyond the pharmaceutical industry’s balance sheets.
- Healthcare Economics: As obesity treatments become more effective and more accessible via oral pills, healthcare systems globally will need to reconsider the cost-benefit analysis of obesity. The long-term savings associated with preventing heart disease, stroke, and diabetes could justify the high cost of these drugs.
- Clinical Practice: The availability of "softer" agents, like those targeting amylin, will likely change the standard of care. Doctors will have a "menu" of options, starting patients on mild, well-tolerated medications and escalating to potent, triple-acting combinations only when necessary.
- Patient Experience: The shift toward monthly injections and daily pills represents a massive improvement in quality of life. For a patient who has struggled with weight for decades, the reduction of the "injection burden" is a major victory for psychological and physical well-being.
As the EASD meeting concludes, the message is clear: we are entering a new era of metabolic medicine. The "blockbuster" era of single-agent GLP-1s is merely the foundation. The next phase will be defined by the nuance of combination therapy, the convenience of oral formats, and the clinical focus on the most vulnerable patients. For the millions living with obesity, the data presented in Milan offers more than just numbers; it offers the promise of a more manageable and sustainable path to health.
About the Author
